Mississippi Administrative Code › Title 30 - Professions and Occupations › Part 2640 - Rules Pertaining to Prescribing, Administering, and Dispensing Medication › Chapter 1 - Rules Pertaining to Prescribing, Administering and Dispensing of Medication › Rule 30-2640-1.5 - Use of Diet Medication

Current through June 25, 2024
Pursuant to Mississippi Code, Section
				  41-29-139(e), it
				  is unlawful for any licensee to prescribe, dispense or administer any
				  medication classified as Schedule II, pursuant to Section
				  41-29-115, for the exclusive
				  treatment of obesity, weight control, or weight loss.
Prescribing or dispensing a controlled substance for weight
				  reduction or the treatment of obesity should be based on accepted scientific
				  knowledge and sound clinical grounds. All such prescribing and dispensing must
				  be in compliance with applicable state and federal laws.
The licensee providing comprehensive treatment of obesity
				  must be present at the facility when he or she prescribes or
				  dispenses1 controlled substances for the purpose of
				  weight reduction or the treatment of obesity. A licensee may administer, order,
				  dispense or prescribe controlled substances for the purpose of weight loss or
				  the treatment of obesity only as an adjunct to a clearly documented
				  comprehensive program of behavior modification, comprehensive nutritional
				  education, and exercise or physical therapy intervention. The licensee must
				  comply with all of the following conditions:
A. An initial comprehensive evaluation is to
				be conducted by and thoroughly recorded by the prescribing licensee prior to
				the prescribing, ordering, dispensing or administering of any drug. Such
				evaluation should include a thorough history and thorough physical exam of the
				patient to include at a minimum:
1. Past
				medical history, past surgical history, social history, family history, weight
				history, dietary history, gynecological history, review of systems, allergies
				and medications.
2. A physical exam
				to include height; weight; blood pressure; pulse; % body fat or waist
				circumference/weight hip ratio; lungs; heart; abdomen; and
				extremities.
3. Appropriate testing
				related to medical weight loss (CBC, comprehensive metabolic profile, lipid
				panel, thyroid panel, EKG, if prior or present history of cardiac disease,
				hypertension, diabetes, dyslipidemia, or strong family history of cardiac
				disease age >60
4. The licensee
				must determine and record the patient's Body Mass Index ("BMI"). No patient
				should receive anorexic medications unless the patient has (i) a BMI of [GRETER
				THAN OR EQUAL TO] 30.0 in a normal otherwise healthy patient, or (ii) a BMI
				[GRETER THAN OR EQUAL TO] 27.0 in an individual with at least one associated
				co-morbidity, or (iii) current body weight [GRETER THAN OR EQUAL TO] 120
				percent of a well-documented, long standing healthy weight that the patient
				maintained after the age of 18, or (iv) body fat [GRETER THAN OR EQUAL TO] 30%
				in females, or body fat [GRETER THAN OR EQUAL TO] 25% in males, or (v)
				waist-hip circumference such that the individual is known to be at increased
				cardiovascular and/or co-morbidity risk because of abdominal visceral fat, or
				presence of a co-morbidity condition or conditions aggravated by the patients
				excessive adiposity. The indication for anorexic therapy must be documented in
				the record and re-evaluated at each visit or with each prescription
				refill.
5. Absolute
				contraindications of Schedule III or IV anorectic drugs for purposes of weight
				loss management are pregnancy, breast feeding, or severe allergic reactions to
				these medications. Relative contraindications of Schedule III and IV anorectics
				for the purpose of weight loss management are uncontrolled bipolar,
				uncontrolled epilepsy, Part 2640, Rule
				1.9, controls in all cases.
				Physician assistants are not permitted to dispense medication.
uncontrolled hypertension, episodic tachyarrhythmia,
				  excessive stimulation, history of substance abuse, severe anticholinergic
				  effects, such as, extreme dryness of mouth or unmanageable constipation should
				  be addressed with licensee prior to starting weight loss medications. Schedule
				  III and IV anorectics can be used in conjunction with any other medications
				  deemed safe by the licensee.